ArticleFrontiers in endocrinology2025
Triglyceride-glucose index as a novel prognostic biomarker for coronary artery disease: evidence from a large-scale prospective cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Head-to-head comparison of the ability of the cardiometabolic index and triglyceride-glucose index to predict 3-year major adverse cardiovascular events in patients with atrial fibrillation: insights from a community cohort.Lipids in health and disease · 2026Article
- Prognostic Value of Composite Biomarkers Integrating Insulin Resistance and Coronary Inflammation for Major Adverse Cardiovascular Events in Post-PCI Patients with Coronary Artery Disease Across Glycemic Status: A Prospective Cohort Study.Journal of inflammation research · 2026Article
- Association of the triglyceride glucose index and its related indices with coronary artery disease risk: mediation by glycated haemoglobin.Frontiers in endocrinology · 2026Article
- Plasma ceramide Cer24:0 and insulin resistance: associations with TyG and TG/HDL-C in a multicenter study of coronary artery disease cohorts.Frontiers in endocrinology · 2026Observational
- Association between triglyceride-glucose index-a body shape index and atherosclerotic cardiovascular disease, and the modification effect of dietary patterns.Frontiers in nutrition · 2026Article
- Triglyceride levels and all-cause mortality in patients with left main coronary artery disease undergoing percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The triglyceride-glucose (TyG) index, combining fasting glucose and triglyceride levels, has emerged as a promising biomarker for coronary artery disease (CAD). However, evidence for its long-term prognostic value in CAD remains limited and inconclusive. Methods: This prospective cohort study was conducted at Beijing Hospital between January 2016 and December 2021, involving 23,591 patients with CAD. Based on the inclusion and exclusion criteria, a total of 11,325 CAD patients were included in the final analysis. TyG index was determined using the formula ln [fasting triglycerides (mg/dL) × fasting glucose. Eligible participants were stratified by TyG tertiles: Tertile 1 (TyG ≤ 8.39, n=3,775); Tertile 2 (8.40 ≤ TyG ≤ 8.92, n=3,776); Tertile 3 (TyG ≥ 8.93, n=3,774), with a median follow-up duration of 28 months. The primary outcomes were all-cause death and cardiovascular disease (CVD) death. The secondary outcome was major adverse cardiovascular events (MACE). Cox proportional hazards models and restricted cubic spline (RCS) analysis were applied to investigate the relationship between the TyG index and endpoints. Results: RCS analyses showed a monotonic increase in all-cause death, CVD death, and MACE risks with higher TyG. Kaplan-Meier curves confirmed worse survival in higher TyG tertiles. Multivariable-adjusted analysis revealed continuous TyG index was an independent risk factor for all-cause death (HR = 1.22; 95% CI 1.02-1.45) and CVD death (HR = 1.61; 95% CI 1.17-2.22). Using the lowest TyG index tertile as the reference (T1), the highest tertile (T3) group exhibited a 1.34-fold risk of all-cause death (95% CI 1.04-1.72), a 1.99-fold risk of CVD death (95% CI 1.23-3.21), and a 1.17-fold higher risk of MACE (95% CI 1.00-1.37), respectively. Subgroup analyses showed the continuous TyG index was significantly associated with the risk of all-cause death in acute coronary syndrome (ACS) (HR = 1.33, 95% CI 1.01-1.74) and CVD death in chronic coronary syndrome (CCS) (HR = 1.79, 95% CI 1.16-2.78). With T1 as the reference, patients with CCS in the T3 group had a 2.15-fold higher risk of CVD death (95% CI 1.10-4.23). Conclusion: The TyG index correlates with increased all-cause death, CVD death, and MACE risks in CAD, with prognostic value in both ACS and CCS, particularly in CCS. These findings establish TyG as a robust CAD biomarker, warranting further clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.